Sunrise Pharmaceuticals

Sunrise Pharmaceuticals

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Sunrise Pharmaceuticals is a private, commercial-stage generics company with a fully integrated model from development to market. Following a strategic refocus on Abbreviated New Drug Applications (ANDAs) in 2012, the company achieved its first ANDA approval in 2014 and now markets products under its own label. It targets the entire US generic drug supply chain, including retailers, wholesalers, distributors, health systems, and government entities, with a stated aim of expanding its robust product pipeline to provide affordable medications.

GenericsSmall Molecules

Technology Platform

Integrated generic drug development and manufacturing platform focused on bioequivalence studies, analytical development, formulation, and regulatory filing of Abbreviated New Drug Applications (ANDAs).

Opportunities

The large and stable US generic drug market, driven by cost-containment pressures and ongoing patent expirations, provides a steady demand base.
Opportunities exist in developing complex generics with higher barriers to entry and in forming strategic partnerships for development or commercialization to expand reach.

Risk Factors

Key risks include intense price competition leading to margin erosion, regulatory compliance failures that can halt production, and costly patent litigation from originator companies when filing Paragraph IV ANDAs.
Supply chain disruptions for APIs also pose a significant operational risk.

Competitive Landscape

Sunrise competes in the highly fragmented and competitive US generic pharmaceutical market against large global players (e.g., Teva, Sandoz, Viatris) and numerous agile private companies. Competition is primarily on price, product portfolio breadth, reliability of supply, and speed to market for new generics.